A Phase 1 interventional study of TCD601 in ALS, sponsored by ITB-Med LLC. Terminated at 3 sites in Sweden. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by ITB-Med LLC · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Amyotrophic Lateral Sclerosis with a site in Sweden — 6 open to participants now, 11 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Sweden.
Among the 34 studies in Amyotrophic Lateral Sclerosis with a site in Sweden, this one is the 34th largest by enrollment, is one of 5 that started in 2024, is the only one in phase 1, and was the 29th registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →6 of the 34 studies in Amyotrophic Lateral Sclerosis with a site in Sweden are open now. Recruiting first, the newest first:
Leal Therapeutics, Inc · Sites in Sweden, Germany, Italy and 1 more country
Ages 18–75
Prilenia · Sites in Sweden, United States, Belgium and 10 more countries
Ages 18–80
Zydus Therapeutics Inc. · Sites in Sweden, United States, Australia and 9 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Sweden, Australia, Belgium and 6 more countries
Ages 18+
AB Science · Sites in Sweden, United States, Belgium and 14 more countries
Ages 18–81
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 19
First in 2009; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 234 across the 34 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 34 have an industry lead sponsor. The 10 most frequent:
ITB-Med LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
ITB-Med LLC has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Amyotrophic Lateral Sclerosis with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Amyotrophic Lateral Sclerosis with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TCD601 (siplizumab) in newly diagnosed adult ALS patients.
The purpose of this study is to investigate how safe and tolerable the study drug siplizumab is when given to adult patients with ALS. The study will examine how the drug is distributed in the body and what effects it has on different immune cells in the blood and in the fluid surrounding the motor neurons (cerebrospinal fluid). In addition, the study will monitor the progression of ALS and look for any changes related to the disease that may occur during the study.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TCD601 (siplizumab) administered with the contemporary standard of care regimen.
Biological: TCD601
Investigational Product
Also known as: siplizumab
Evaluation of the safety of TCD601 in adult patients with ALS
Assess the incidence of treatment-emergent Adverse Events \[Safety and Tolerability\]
Time frame: 12 Months
Evaluation of the pharmacokinetics (PK)
Siplizumab concentration over time
Time frame: 12 Months
Correlation of ALS disease status with leucocyte phenotypic profiles
The ALS disease status measured by ALSFRS and Kings staging will be compared with the leucocyte phenotypes measured by FACS analysis.
Time frame: 12 Months
Evaluation of levels of biomarkers
Neurofilament light chain levels over time
Time frame: 12 Months
Length of time from trial entry to tracheostomy / death
The time from study enrollment to patient death or tracheostomy will be measured.
Time frame: 12 Months
Assessment of clinically relevant changes in laboratory measurements
Incidence of abnormal laboratory values
Time frame: 12 Months
Evaluation of pharmacodynamics (PD) of TCD601
Lymphocyte counts by subset over time
Time frame: 12 Months
Assessment of clinically relevant changes in vital signs
Incidence of abnormal vital signs
Time frame: 12 Months
Ran from Apr 2024 to primary completion in Jul 2026, 26 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Siplizumab
Amyotrophic Lateral Sclerosis →
ITB-Med LLC